Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

New Drug Duo Helps Cut Colon Cancer Risk


Related Encyclopedia
 border=
Adenocarcinoma of the Lung and Brain Metastases
Arteriohepatic Dysplasia
Basal Cell Carcinoma
Bladder Cancer
More...

Related Healthscout Videos
 border=
Nature’s Remedies
Critical Nutrition
Space Age Dental Scan
Detecting Lung Disease
More...

Related Animations
 border=
Breast Self-Exam Video
Colon Cancer
Hepatitis
More...

Related Drug Information
 border=
Epogen
Iressa
Procrit
Topamax
More...

Related News Articles
 border=
Gender Plays Role in Kidney Transplant Outcomes
Kidney Cancer Vaccine Shows No Boost in Survival
New Drug Slows Thyroid Cancer
Hallucinogen Gives Lasting Spiritual Boost
More...


Page:  << Prev | 1 | 2 | 3

The drug appears to work by controlling the growth of blood vessels, which is how this type of liver cancer is able to spread so rapidly.

At 12 weeks, one patient had a partial response and 17 saw their disease stabilize. Progression-free survival lasted an average of four months, and overall survival was 10 months, the researchers report.

"Even though the response rate to make the tumor smaller was observed in only one patient, 50 percent of the patients had stable disease and are doing well," Zhu said. "Sunitinib can be safely given, with close monitoring, to the majority of these patients," he said.

Text Continues Below



The treatment was well-tolerated, and there were low rates of all blood disorders, the researchers report. Because Sutent has been associated with increased risk of heart problems, all patients taking Sutent -- but especially those who have risks for heart disease -- need careful monitoring and treatment for high blood pressure and other signs of heart problems.

In a third report, researchers from the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia found that blood pressure-lowering drugs called angiotensin receptor blockers appear to retard pancreatic cancer cell growth and cause malignant cells to die.

This type of drug is able to inhibit the function of the hormone angiotensin II in the pancreas. The same receptor is found in pancreatic cancer cells. In laboratory experiments, the researchers found that the drug was able to block the production of a growth factor called VEGF, which helps spur the growth of tumor blood vessels.

"This is really exciting because the role of this receptor has never been known," lead researcher Dr. Hwyda Arafat said in a prepared statement. "It's never been connected to cell division or apoptosis. We're also now further exploring the mechanisms involved. The exciting thing is that this receptor already has so many available pharmaceutical blockers on the market." Ultimately, the group hopes to be able to test these agents in human trials, she said.

More information

For more information on cancer, visit the American Cancer Society .

Page:  << Prev | 1 | 2 | 3

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 4/15/2008

Related Links
 border=
From Healthscout's partner site on acid reflux, AcidRefluxConnection.com
SYMPTOMS: Learn about the symptoms of acid reflux disease
DRUGS: Common medications used to treat heartburn
TREATMENT: Lifestyle changes, medication, and surgeryoptions





New Features

New ADHD Site!

SOURCES: April 14, 2008, teleconference with: Andrew Zhu, M.D., Ph.D., assistant professor, medicine, Harvard Medical School, Boston; Frank L. Meyskens, M.D., professor, medicine, University of California, Irving; April 14, 2008, presentations, American Association for Cancer Research annual meeting, San Diego


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map